<DOC>
	<DOCNO>NCT00005644</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient advanced cancer urothelium decrease kidney function .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Cancer Urothelium Decreased Kidney Function</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient progressive regional metastatic transitional cell carcinoma urothelium renal insufficiency treat paclitaxel gemcitabine . - Determine toxicity regimen patient population . OUTLINE : Patients receive paclitaxel IV 1 hour follow immediately gemcitabine IV 30 minute day 1 , 8 , 15 . Treatment continue every 4 week minimum 3 course absence unacceptable toxicity disease progression . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 10-27 patient accrue study within 10-27 month .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Ureteral Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive regional metastatic transitional cell carcinoma urothelium Mixed histology contain component transitional cell carcinoma allow Bidimensionally measurable disease No clinical evidence CNS metastases Clinically unsuspected organconfined prostate cancer find time cystoprostatectomy allow PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2.5 time upper limit normal ( ULN ) alkaline phosphatase normal OR Alkaline phosphatase great 4 time ULN SGOT normal OR SGOT le 1.5 time ULN alkaline phosphatase less 2.5 time ULN Renal : Creatinine great 3.0 mg/dL Glomerular filtration rate great 50 mL/min Cardiovascular : No history American Heart Association class III IV heart disease No uncontrolled congestive heart failure No severe cardiac arrhythmia Other : Not pregnant nursing Fertile patient must use effective contraception No preexist peripheral neuropathy grade 2 great No active unresolved infection require parenteral antibiotic within past 7 day No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic biologic response modifier therapy advance disease Prior intravesical BCG superficial disease allow Chemotherapy : Prior intravesical chemotherapy superficial disease allow No prior chemotherapy advance disease At least 6 month since prior adjuvant/neoadjuvant methotrexate , vinblastine , doxorubicin , cisplatin ( MVAC ) cisplatin , methotrexate , vinblastine ( CMV ) , cisplatin radiosensitizer Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : See Disease Characteristics At least 4 week since prior major surgery recover Other : No concurrent hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>stage III bladder cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>recurrent urethral cancer</keyword>
	<keyword>distal urethral cancer</keyword>
	<keyword>proximal urethral cancer</keyword>
	<keyword>urethral cancer associate invasive bladder cancer</keyword>
	<keyword>metastatic transitional cell cancer renal pelvis ureter</keyword>
	<keyword>regional transitional cell cancer renal pelvis ureter</keyword>
	<keyword>recurrent transitional cell cancer renal pelvis ureter</keyword>
</DOC>